Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290050 · ClinicalTrials.gov registry record · Phase 1
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06290050 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 20 participants.
The verdict
NCT06290050, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone or together with midazolam or repaglinide. During the study, participants will need to stay at the clinic for 19 days. Blood samples will be taken at several timepoints during the study. The study drug will be given by mouth (orally).
Interventions
- DRUG Midazolam
- DRUG TAK-279
- DRUG Repaglinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290050
The ClinicalTrials.gov registry entry for NCT06290050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT06290050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06290050 about?
NCT06290050 is a clinical study titled "A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults". The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone...
What is the current status of trial NCT06290050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-03-29. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT06290050?
The interventions under investigation include: Midazolam (DRUG), TAK-279 (DRUG), Repaglinide (DRUG).
Who is sponsoring clinical trial NCT06290050?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.